Tysabri natalizumab: Phase IIIb started

Biogen Idec and Elan began the double-blind, placebo-controlled, international Phase IIIb ASCEND trial to evaluate 300 mg IV Tysabri every 4 weeks for 96 weeks in about 850 patients. Biogen Idec and p...